Recent studies have indicated that anti‐PD‐1 antibody therapy were effective for patients with refractory and relapsed Hodgkin's lymphoma, advanced multiple myeloma, and melanoma 12, 13, 14. The gene discussed is PDCD1; the disease is Hodgkins lymphoma.